Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research units
Publications
Datasets
Search by expertise, name or affiliation
Programming the immune checkpoint to treat hematologic malignancies
Eric Vick,
Daruka Mahadevan
Research output
:
Contribution to journal
›
Review article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Programming the immune checkpoint to treat hematologic malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Combination Therapy
100%
Hematologic Malignancy
60%
Cancer
40%
Monoclonal Antibody
20%
Immune Response
20%
Side Effect
20%
Malignant Neoplasm
20%
Adverse Event
20%
Tumor Cell
20%
Hodgkin's Lymphoma
20%
Immune System
20%
CTLA-4
20%
Tumor Microenvironment
20%
Development
20%
Diffuse Large B-Cell Lymphoma
20%
Immunological Tolerance
20%
B-Cell Chronic Lymphocytic Leukemia
20%
Follicular Lymphoma
20%
Lymphosarcoma
20%
Cells
20%
Base
20%
Therapeutic Procedure
20%
Patient
20%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
80%
Hematologic Malignancy
60%
Programmed Death-Ligand 1
40%
Adverse Event
20%
Monoclonal Antibody
20%
Side Effect
20%
Hodgkin Disease
20%
Diffuse Large B Cell Lymphoma
20%
Malignant Neoplasm
20%
Follicular Lymphoma
20%
Chronic Lymphatic Leukemia
20%
Cytotoxic T Lymphocyte Antigen 4
20%
Tumor Microenvironment
20%
Base
20%
Lymphosarcoma
20%